3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Breast Neoplasms
19
Neoplasms
11
Polycystic Ovary Syndrome
9
Neoplasm Metastasis
4
Multiple Myeloma
4
Melanoma
4
Vomiting
3
Prostatic Neoplasms
3
Leukemia, Myeloid, Acute
3
Head and Neck Neoplasms
3
Endometrial Neoplasms
3
Triple Negative Breast Neoplasms
2
Solid Tumors
2
Skin Neoplasms
2
Sarcoma
2
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Peripheral Nervous System Diseases
2
Ovarian Neoplasms
2
Obesity
2
Nausea
2
Lung Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, B-Cell
2
Leukemia
2
Insulin Resistance
2
Inflammation
2
Diabetes Mellitus
2
Colorectal Neoplasms
2
Cognitive Dysfunction
2
Interventions
fludarabine phosphate
25
Cyclophosphamide
24
Peripheral Blood Stem Cell Transplantation
23
Busulfan
17
Tacrolimus
15
Methotrexate
13
Cyclosporine
13
ruxolitinib
12
Whole-Body Irradiation
12
Mycophenolic Acid
12
Antilymphocyte Serum
11
Filgrastim
8
Decitabine
7
fludarabine
6
Etoposide
6
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
6
peginterferon alfa-2a
5
Radiotherapy
5
Methylprednisolone
5
Cytarabine
5
Carboplatin
5
Prednisone
4
Melphalan
4
Biopsy
4
Aspirin
4
givinostat hydrochloride
3
givinostat
3
bomedemstat
3
anagrelide
3
Topotecan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Thrombocythemia, Essential
×
Tablets
×
Clear all
NCT04243122
2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2
Completed
44 enrolled